- Title: Subtitle
- Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
- Creators
- Noopur Raje - Massachusetts General HospitalNizar Jacques Bahlis - University of CalgaryCaitlin Costello - University of California San DiegoBhagirathbhai Dholaria - Vanderbilt University Medical CenterMelhem Solh - Northside HospitalMoshe Yair Levy - Scott & White HospitalMichael H Tomasson - University of IowaMichael A. Damore - Pfizer (United States)Sibo Jiang - Pfizer (United States)Cynthia Basu - Pfizer (United States)Athanasia Skoura - Pfizer (United States)Edward M Chan - Pfizer (United States)Suzanne Trudel - Princess Margaret Cancer CentreAndrzej Jakubowiak - University of Chicago Medical CenterMichael P Chu - Cross Cancer InstituteCristina J. Gasparetto - Duke UniversityAndrew P. Dalovisio - Ochsner Health SystemMichael Sebag - McGill University Health CentreAlexander M Lesokhin - Memorial Sloan Kettering Cancer Center
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.388-390
- DOI
- 10.1182/blood-2022-166494
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health, Sport, and Human Physiology ; Internal Medicine
- Record Identifier
- 9984363260802771
Abstract
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
Blood, Vol.140(Supplement 1), pp.388-390
11/15/2022
DOI: 10.1182/blood-2022-166494
Details
Metrics
265 Record Views